<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NATAMYCIN</span><br/>(na-ta-mye'sin)<br/><span class="topboxtradename">Natacyn<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antifungal agent</span><br/><b>Prototype: </b>Amphotericin B<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5% suspension</p>
<h1><a name="action">Actions</a></h1>
<p>Mechanism of action simulates that of amphotericin B and nystatin by binding to sterols in the fungal cell membrane.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against many yeasts and filamentous fungi including <i>Candida, Aspergillus,</i>
<i>Cephalosporium, Fusarium,</i> and <i>Penicillium</i>. Limited activity in vivo against <i>Trichomonas vaginalis</i>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Blepharitis, conjunctivitis, and keratitis caused by susceptible fungi. Drug of choice for <i>Fusarium solani</i> keratitis.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Oral, cutaneous, and vaginal candidiasis; intranasal treatment of pulmonary aspergillosis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Concomitant administration of a corticosteroid.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category C) or lactation. Safety and efficacy in children are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Fungal Keratitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Ophthalmic</span> 1 drop in conjunctival sac of infected eye q12h for 34 d, then decrease to 1 drop q68h, then gradually decrease
               to 1 drop q47d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Instillation</span><br/><ul>
<li>Wash hands thoroughly before and after treatment. Infection is easily transferred from infected to noninfected eye and to
            other individuals.
         </li>
<li>Shake well before using.</li>
<li>Store at 2°24° C (36°75° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Special Senses:</span> Blurred vision, photophobia, eye pain. Uneven adherence of suspension to epithelial ulcerations or in fornices. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Drug adheres to ulcerated surface of the cornea and is retained in conjunctival fornices. Does not appear to be systemically
      absorbed. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Inspect eye for response and tolerance at least twice weekly.</li>
<li>
            							Note: Lack of improvement in keratitis within 710 d suggests that causative organisms may not be susceptible to natamycin.
            Reevaluation is indicated and possibly a change in therapy.
            						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn appropriate technique for application of eye drops.</li>
<li>Expect temporary light sensitivity. Be prepared to wear sunglasses outdoors after drug administration and perhaps for a few
            hours indoors.
         </li>
<li>Return to ophthalmologist for reevaluation of eye problem if you experience symptoms of conjunctivitis: pain, discharge, itching,
            scratching "foreign body sensation," changes in vision.
         </li>
<li>Do not share facecloths and hand towels; this will help prevent transmission of the fungal infection.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>